Get the Stockscreener App
15.70
0.96%
0.15
Uniqure N V stock is traded at $15.70, with a volume of 1.04M.
It is up +0.96% in the last 24 hours and up +10.18% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$15.55
Open:
$15.6
24h Volume:
1.04M
Relative Volume:
0.88
Market Cap:
$861.41M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.4228
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-2.97%
1M Performance:
+10.18%
6M Performance:
+22.27%
1Y Performance:
+141.35%
1-Day Range:
$15.52
$16.43
1-Week Range:
$14.70
$16.43
52-Week Range:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.70 | 859.22M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure N.V. Facing Inflection Point in Trend AnalysisJuly 2025 Trends & AI Enhanced Execution Alerts - beatles.ru
Short Term Trend Reversal in uniQure N.V. PossibleJuly 2025 Fed Impact & Free High Accuracy Swing Entry Alerts - 선데이타임즈
What to expect from uniQure N.V. in the next 30 daysTrade Volume Report & Consistent Return Strategy Ideas - Newser
Visual analytics tools that track uniQure N.V. performanceJuly 2025 Breakouts & AI Powered Market Trend Analysis - Newser
Smart tools for monitoring uniQure N.V.’s price actionWeekly Trade Review & Free Technical Confirmation Trade Alerts - Newser
Using fundamentals and technicals on uniQure N.V.Market Activity Recap & Entry Point Confirmation Signals - Newser
How to use Fibonacci retracement on uniQure N.V.Quarterly Portfolio Report & Long-Term Growth Portfolio Plans - Newser
uniQure N.V’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
Momentum divergence signals in uniQure N.V. chart2025 Market Trends & Fast Entry High Yield Stock Tips - Newser
How uniQure N.V. stock performs during market volatilityBull Run & Real-Time Chart Breakout Alerts - Newser
Biotech And Pharma Stocks Rally After Positive News And Upgrades - Finimize
UniQure Shares Rise After Mizuho Upgrade - MarketScreener
Mizuho Securities Upgrades UniQure NV(QURE.US) to Buy Rating, Announces Target Price $30 - 富途牛牛
uniQure stock rating upgraded by Mizuho on Huntington’s disease therapy potential - Investing.com
How sentiment analysis helps forecast uniQure N.V.ROI Focused Setup Screener With Exit Markers - Newser
uniQure N.V. stock trend outlook and recovery pathPortfolio Review Summary with Five-Year Outlook - Newser
Will uniQure N.V. price bounce be sustainableWeekly Breakout Forecast with Entry Zones - Newser
Institutional Ownership Dominates uniQure N.V., Hedge Funds Hold 19% - AInvest
uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - uk.finance.yahoo.com
Uniqure N.V. shares rise 1.04% after-hours following PTC Therapeutics' positive Q2 earnings report. - AInvest
Aberdeen Group Expands Stake in uniQure with Strategic Acquisition - AInvest
Aberdeen Group plc Expands Stake in uniQure NV with Strategic Ac - GuruFocus
How high can uniQure N.V. stock price go in 2025AI Powered Buy Point Forecast Planner - Newser
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Wall Street Zen - Defense World
Is uniQure N.V. a good long term investmentGet exclusive access to premium stock research - Jammu Links News
What is uniQure N.V. company’s growth strategyStrongest growth potential - Jammu Links News
Should I hold or sell uniQure N.V. stock in 2025Unlock daily market insights for better trades - Jammu Links News
What makes uniQure N.V. stock price move sharplyBuild a strong portfolio for long-term success - Jammu Links News
What drives uniQure N.V. stock priceUnprecedented market success - Jammu Links News
Is uniQure N.V. a growth stock or a value stockMaximize returns with disciplined investment techniques - Jammu Links News
What is the risk reward ratio of investing in uniQure N.V. stockOutstanding growth strategies - Jammu Links News
What are the latest earnings results for uniQure N.V.Discover undervalued stocks before they soar - Jammu Links News
How does uniQure N.V. compare to its industry peersMaximize your gains with expert trading tips - Jammu Links News
Is uniQure N.V. stock overvalued or undervaluedDiscover high-impact stocks for your portfolio - Jammu Links News
What analysts say about uniQure N.V. stockDiscover breakthrough stocks before the crowd - Jammu Links News
How strong is uniQure N.V. company’s balance sheetBuild wealth faster with professional insights - Jammu Links News
What are the technical indicators suggesting about uniQure N.V.High-octane gains - Jammu Links News
What is HC Wainwright’s Forecast for uniQure Q3 Earnings? - Defense World
Why is uniQure N.V. stock attracting strong analyst attentionEntry Signal Signals To Watch Now - Jammu Links News
UniQure N.V. (NASDAQ:QURE) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
uniQure Reports Q2 2025 Progress and Financials - TipRanks
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Zacks Investment Research
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Springhorn Jeremy P. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,694 |
| POST LEONARD E | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
29,937 |
| Kaye Jack | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
20,439 |
| Jacques Rachelle Suzanne | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
28,346 |
| Gut Robert | Director |
Jun 20 '25 |
Sale |
14.45 |
3,336 |
48,205 |
56,879 |
| Balachandran Madhavan | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
37,697 |
| Meek David D. | Director |
Jun 20 '25 |
Sale |
14.45 |
2,112 |
30,518 |
34,190 |
| Potts Jeannette | Chief Legal Officer |
Jun 16 '25 |
Sale |
15.14 |
4,670 |
70,704 |
115,073 |
| Kapusta Matthew C | CEO, Managing Director |
Mar 04 '25 |
Sale |
10.29 |
28,341 |
291,629 |
651,454 |
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):